333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer

MLA

Hannah M. Linden, et al. “333TiP AMEERA-1: Phase I/II Study of Amcenestrant (SAR439859), an Oral Selective Estrogen Receptor (ER) Degrader (SERD), with Alpelisib in Postmenopausal Women with ER+/ Human Epidermal Growth Factor Receptor 2-Negative (HER2–) PIK3CA-Mutated Advanced Breast Cancer.” Annals of Oncology, vol. 32, Sept. 2021, pp. S511–12. EBSCOhost, https://doi.org/10.1016/j.annonc.2021.08.616.

APA

Hannah M. Linden, Simon Lord, S. Cartot-Cotton, Vasiliki Pelekanou, A. Gosselin, M. Campone, Sarat Chandarlapaty, Patrick Neven, Aditya Bardia, Valentina Boni, Peter Kabos, & Marina Celanovic. (2021). 333TiP AMEERA-1: Phase I/II study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with alpelisib in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2–) PIK3CA-mutated advanced breast cancer. Annals of Oncology, 32, S511–S512. https://doi.org/10.1016/j.annonc.2021.08.616

Chicago

Hannah M. Linden, Simon Lord, S. Cartot-Cotton, Vasiliki Pelekanou, A. Gosselin, M. Campone, Sarat Chandarlapaty, et al. 2021. “333TiP AMEERA-1: Phase I/II Study of Amcenestrant (SAR439859), an Oral Selective Estrogen Receptor (ER) Degrader (SERD), with Alpelisib in Postmenopausal Women with ER+/ Human Epidermal Growth Factor Receptor 2-Negative (HER2–) PIK3CA-Mutated Advanced Breast Cancer.” Annals of Oncology 32 (September): S511–12. doi:10.1016/j.annonc.2021.08.616.